<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985201</url>
  </required_header>
  <id_info>
    <org_study_id>2020LY025</org_study_id>
    <nct_id>NCT04985201</nct_id>
  </id_info>
  <brief_title>Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy</brief_title>
  <official_title>Clinical Study of Irinotecan With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study was designed to evaluate the safety and efficacy of irinotecan in&#xD;
      combination with simvastatin compared with treatment with irinotecan alone in ES-SCLC&#xD;
      patients relapsed from first-line chemotherapy. Participants will be divided in a 1:1 ratio&#xD;
      to receive either irinotecan (4 cycles) + simvastatin (10 months) or irinotecan (4 cycles)&#xD;
      until progressive disease (PD) as assessed by the investigator using Response Evaluation&#xD;
      Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until&#xD;
      persistent radiographic PD or symptomatic deterioration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I.To evaluate the progression-free survival (PFS) of patients with extensive stage-small cell&#xD;
      lung cancer (ES-SCLC) treated with irinotecan + simvastatin or with irinotecan alone.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I.To assess best overall response rate (ORR) after treatment. II.To assess disease control&#xD;
      rate (DCR) after treatment.&#xD;
&#xD;
      III.To estimate overall survival (OS) of patients with ES-SCLC. IV. To evaluate the toxicity&#xD;
      profile of irinotecan + simvastatin.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I.To evaluate biomarkers correlatives. II.To explore the mechanism of irinotecan +&#xD;
      simvastatin in the treatment of chemotherapy-resistant participants with ES-SCLC.&#xD;
&#xD;
      OUTLINE: Patients are divided into two arms. ARM A: Participants received intravenous&#xD;
      infusions of irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day&#xD;
      cycle (4 cycles) in combination with oral simvastatin (40mg daily) （10 months）until&#xD;
      persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of&#xD;
      consent, death, or study termination by the Sponsor.&#xD;
&#xD;
      ARM B:Participants received intravenous infusions of irinotecan 60 milligrams per square&#xD;
      meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles) until persistent radiographic PD,&#xD;
      symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study&#xD;
      termination by the Sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the progression-free survival (PFS) of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To assess disease control rate (DCR) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To assess best overall response rate (ORR) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>To estimate overall survival (OS) of patients with ES-SCLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events (AE) as assessed by CTCAE v4.0</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the toxicity profile.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Simvastatin + Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles) in combination with oral simvastatin (20mg daily) (10 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received intravenous infusions of Irinotecan 60 milligrams per square meter (mg/m^2) on Day 1,8 of every 21-day cycle (4 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan intravenous infusion was administered at a dose of 60 mg/m^2 on Day 1,8 of each 21-day cycle.</description>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_label>Simvastatin + Irinotecan</arm_group_label>
    <other_name>Irinotecan injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 40 mg daily oral tablet taken.</description>
    <arm_group_label>Simvastatin + Irinotecan</arm_group_label>
    <other_name>Simvastatin 40mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must be volunteered to participate in the clinical trial. Patients must sign the&#xD;
        informed Consent form (ICF) and be willing to follow and be able to complete all test&#xD;
        procedures.&#xD;
&#xD;
        Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung&#xD;
        Study Group [VALG] staging system).&#xD;
&#xD;
        No patients with resectable or radical radiotherapy lung cancer. Patient must have no&#xD;
        Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic lymphoma kinase (ALK)&#xD;
        rearrangement, or ROS proto-oncogene 1 , receptor tyrosine kinase(ROS1) rearrangement.&#xD;
&#xD;
        Patient must be at least resistant to the first-line chemotherapy. Patients must have&#xD;
        measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.&#xD;
&#xD;
        Patients can tolerate chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Unclear diagnosis of SCLC. Resectable or radical radiotherapy SCLC. Contraindicated&#xD;
        chemotherapy. Undergoing other active malignancies within 5 years or at the same&#xD;
        time.Patients with localized curable tumors, such as basal cell carcinoma, squamous cell&#xD;
        carcinoma, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in&#xD;
        situ, or breast carcinoma in situ, will not be excluded.&#xD;
&#xD;
        Positive test result for human immunodeficiency virus (HIV). Positive test result for&#xD;
        active tuberculosis. Live vaccine was administered within 28 days of initial&#xD;
        administration. Inactivated viral vaccines for seasonal influenza are allowed, except for&#xD;
        live attenuated intranasal vaccines.&#xD;
&#xD;
        Pregnant or lactating women. A history of psychotropic substance abuse, drug abuse, or&#xD;
        alcoholism. Other factors assessed by the sponsors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yayi He, MD,PHD</last_name>
    <phone>+86 21 65115006</phone>
    <email>doctorjael@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongbin Ji, PHD</last_name>
      <phone>+86-21-54921108</phone>
      <email>hbji@sibcb.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Hongbin Ji, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai pulmonary hospital, Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yayi He, MD,PHD</last_name>
      <phone>+86 21 65115006</phone>
      <email>doctorjael@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yayi He, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.</citation>
    <PMID>33285097</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelsomino F, Tiseo M, Barbieri F, Riccardi F, Cavanna L, Frassoldati A, Delmonte A, Longo L, Dazzi C, Cinieri S, Colantonio I, Sperandi F, Lamberti G, Brocchi S, Tofani L, Boni L, Ardizzoni A. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). Br J Cancer. 2020 Jul;123(1):26-32. doi: 10.1038/s41416-020-0845-3. Epub 2020 Apr 29. Erratum in: Br J Cancer. 2021 Jul;125(2):306.</citation>
    <PMID>32346071</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Li X, Zhang R, Xia Y, Shao Z, Mei Z. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res. 2019 Mar;141:357-365. doi: 10.1016/j.phrs.2019.01.016. Epub 2019 Jan 11.</citation>
    <PMID>30641276</PMID>
  </results_reference>
  <results_reference>
    <citation>Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene. 2006 Feb 9;25(6):877-87.</citation>
    <PMID>16170339</PMID>
  </results_reference>
  <results_reference>
    <citation>Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.</citation>
    <PMID>12467231</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Yayi He</investigator_full_name>
    <investigator_title>Vice-Professor</investigator_title>
  </responsible_party>
  <keyword>ES-SCLC</keyword>
  <keyword>Chemo-resistance</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD is not available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

